These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
282 related articles for article (PubMed ID: 34020460)
1. Antithrombotic therapy for stroke prevention in patients with atrial fibrillation who survive an intracerebral haemorrhage: results of an EHRA survey. Ivany E; Lane DA; Dan GA; Doehner W; Farkowski MM; Iliodromitis K; Lenarczyk R; Potpara TS Europace; 2021 May; 23(5):806-814. PubMed ID: 34020460 [TBL] [Abstract][Full Text] [Related]
2. Antithrombotic therapy in atrial fibrillation associated with valvular heart disease: a joint consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE). Lip GYH; Collet JP; Caterina R; Fauchier L; Lane DA; Larsen TB; Marin F; Morais J; Narasimhan C; Olshansky B; Pierard L; Potpara T; Sarrafzadegan N; Sliwa K; Varela G; Vilahur G; Weiss T; Boriani G; Rocca B; Europace; 2017 Nov; 19(11):1757-1758. PubMed ID: 29096024 [TBL] [Abstract][Full Text] [Related]
3. Antithrombotic treatment management in low stroke risk patients undergoing cardioversion of atrial fibrillation <48 h duration: results of an EHRA survey. Migliore F; Providencia R; Farkowski MM; Dan GA; Daniel S; Potpara TS; Jubele K; Chun JKR; de Asmundis C; Zorzi A; Boveda S Europace; 2021 Sep; 23(9):1502-1507. PubMed ID: 33990842 [TBL] [Abstract][Full Text] [Related]
4. Post-Intracranial Hemorrhage Antithrombotic Therapy in Patients With Atrial Fibrillation. Lin SY; Chang YC; Lin FJ; Tang SC; Dong YH; Wang CC J Am Heart Assoc; 2022 Mar; 11(6):e022849. PubMed ID: 35243876 [TBL] [Abstract][Full Text] [Related]
5. Long-term outcome after anticoagulation-associated intracerebral haemorrhage with or without restarting antithrombotic therapy. Gathier CS; Algra A; Rinkel GJ; van der Worp HB Cerebrovasc Dis; 2013; 36(1):33-7. PubMed ID: 23920426 [TBL] [Abstract][Full Text] [Related]
6. Antithrombotic treatment in patients with atrial fibrillation and acute coronary syndromes: results of the European Heart Rhythm Association survey. Lane DA; Dagres N; Dan GA; García Seara J; Iliodromitis K; Lenarczyk R; Lip GYH; Mansourati J; Marín F; Scherr D; Potpara TS Europace; 2019 Jul; 21(7):1116-1125. PubMed ID: 30874724 [TBL] [Abstract][Full Text] [Related]
7. Antithrombotic Treatment Following Intracerebral Hemorrhage in Patients With and Without Atrial Fibrillation. Pennlert J; Asplund K; Carlberg B; Wiklund PG; Wisten A; Åsberg S; Eriksson M Stroke; 2015 Aug; 46(8):2094-9. PubMed ID: 26159794 [TBL] [Abstract][Full Text] [Related]
8. Quality of life and patient satisfaction in patients with atrial fibrillation on stable vitamin K antagonist treatment or switched to a non-vitamin K antagonist oral anticoagulant during a 1-year follow-up: A PREFER in AF Registry substudy. De Caterina R; Brüggenjürgen B; Darius H; Köhler S; Lucerna M; Pecen L; Renda G; Schilling RJ; Schliephacke T; Zamorano JL; Le Heuzey JY; Kirchhof P Arch Cardiovasc Dis; 2018 Feb; 111(2):74-84. PubMed ID: 28942115 [TBL] [Abstract][Full Text] [Related]
9. Antithrombotic therapy use in patients with atrial fibrillation before the era of non-vitamin K antagonist oral anticoagulants: the Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) Phase I cohort. Huisman MV; Ma CS; Diener HC; Dubner SJ; Halperin JL; Rothman KJ; Teutsch C; Schoof N; Kleine E; Bartels DB; Lip GY; Europace; 2016 Sep; 18(9):1308-18. PubMed ID: 27335063 [TBL] [Abstract][Full Text] [Related]
11. Therapy persistence in newly diagnosed non-valvular atrial fibrillation treated with warfarin or NOAC. A cohort study. Martinez C; Katholing A; Wallenhorst C; Freedman SB Thromb Haemost; 2016 Jan; 115(1):31-9. PubMed ID: 26246112 [TBL] [Abstract][Full Text] [Related]
12. Epidemiology and outcomes of intracerebral hemorrhage associated with oral anticoagulation over 10 years in a population-based stroke registry. Gabriele F; Foschi M; Conversi F; Ciuffini D; De Santis F; Orlandi B; De Santis F; Ornello R; Sacco S Int J Stroke; 2024 Jun; 19(5):515-525. PubMed ID: 37997897 [TBL] [Abstract][Full Text] [Related]
13. Fatal intracranial haemorrhage occurring after oral anticoagulant treatment initiation for secondary stroke prevention in patients with atrial fibrillation. Tsivgoulis G; Katsanos AH; Seiffge DJ; Paciaroni M; Wilson D; Koga M; Macha K; Cappellari M; Kallmünzer B; Polymeris AA; Toyoda K; Caso V; Werring DJ; Engelter ST; De Marchis GM; Eur J Neurol; 2020 Aug; 27(8):1612-1617. PubMed ID: 32333493 [TBL] [Abstract][Full Text] [Related]
14. Updated European Heart Rhythm Association practical guide on the use of non-vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation: Executive summary. Heidbuchel H; Verhamme P; Alings M; Antz M; Diener HC; Hacke W; Oldgren J; Sinnaeve P; Camm AJ; Kirchhof P; Eur Heart J; 2017 Jul; 38(27):2137-2149. PubMed ID: 27282612 [TBL] [Abstract][Full Text] [Related]
15. How do anticoagulated atrial fibrillation patients who suffer ischemic stroke or spontaneous intracerebral hemorrhage differ? Lehtola H; Hartikainen J; Hartikainen P; Kiviniemi T; Nuotio I; Palomäki A; Ylitalo A; Airaksinen KEJ; Mustonen P Clin Cardiol; 2018 May; 41(5):608-614. PubMed ID: 29745996 [TBL] [Abstract][Full Text] [Related]
16. Management of atrial fibrillation in patients with chronic kidney disease in clinical practice: a joint European Heart Rhythm Association (EHRA) and European Renal Association/European Dialysis and Transplantation Association (ERA/EDTA) physician-based survey. Potpara TS; Ferro C; Lip GYH; Dan GA; Lenarczyk R; Mallamaci F; Ortiz A; Sarafidis P; Ekart R; Dagres N Europace; 2020 Mar; 22(3):496-505. PubMed ID: 31965154 [TBL] [Abstract][Full Text] [Related]
17. Antithrombotic Therapy in Atrial Fibrillation Associated with Valvular Heart Disease: Executive Summary of a Joint Consensus Document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, Endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE). Lip GYH; Collet JP; de Caterina R; Fauchier L; Lane DA; Larsen TB; Marin F; Morais J; Narasimhan C; Olshansky B; Pierard L; Potpara T; Sarrafzadegan N; Sliwa K; Varela G; Vilahur G; Weiss T; Boriani G; Rocca B Thromb Haemost; 2017 Dec; 117(12):2215-2236. PubMed ID: 29212110 [TBL] [Abstract][Full Text] [Related]
18. Stroke-prevention strategies in North American patients with atrial fibrillation: The GLORIA-AF registry program. McIntyre WF; Conen D; Olshansky B; Halperin JL; Hayek E; Huisman MV; Lip GYH; Lu S; Healey JS Clin Cardiol; 2018 Jun; 41(6):744-751. PubMed ID: 29546729 [TBL] [Abstract][Full Text] [Related]
19. 'Real-world' antithrombotic treatment in atrial fibrillation: The EORP-AF pilot survey. Lip GY; Laroche C; Dan GA; Santini M; Kalarus Z; Rasmussen LH; Ioachim PM; Tica O; Boriani G; Cimaglia P; Diemberger I; Hellum CF; Mortensen B; Maggioni AP Am J Med; 2014 Jun; 127(6):519-29.e1. PubMed ID: 24486284 [TBL] [Abstract][Full Text] [Related]